Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Inorg Biochem ; 100(5-6): 1075-90, 2006 May.
Article in English | MEDLINE | ID: mdl-16403573

ABSTRACT

In flavocytochrome P450 BM3 there are several active site residues that are highly conserved throughout the P450 superfamily. Of these, a phenylalanine (Phe393) has been shown to modulate heme reduction potential through interactions with the implicitly conserved heme-ligand cysteine. In addition, a distal threonine (Thr268) has been implicated in a variety of roles including proton donation, oxygen activation and substrate recognition. Substrate binding in P450 BM3 causes a shift in the spin state from low- to high-spin. This change in spin-state is accompanied by a positive shift in the reduction potential (DeltaE(m) [WT+arachidonate (120 microM)]=+138 mV). Substitution of Thr268 by an alanine or asparagine residue causes a significant decrease in the ability of the enzyme to generate the high-spin complex via substrate binding and consequently leads to a decrease in the substrate-induced potential shift (DeltaE(m) [T268A+arachidonate (120 microM)]=+73 mV, DeltaE(m) [T268N+arachidonate (120 microM)]=+9 mV). Rate constants for the first electron transfer and for oxy-ferrous decay were measured by pre-steady-state stopped-flow kinetics and found to be almost entirely dependant on the heme reduction potential. More positive reduction potentials lead to enhanced rate constants for heme reduction and more stable oxy-ferrous species. In addition, substitutions of the threonine lead to an increase in the production of hydrogen peroxide in preference to hydroxylated product. These results suggest an important role for this active site threonine in substrate recognition and in maintaining an efficiently functioning enzyme. However, the dependence of the rate constants for oxy-ferrous decay on reduction potential raises some questions as to the importance of Thr268 in iron-oxo stabilisation.


Subject(s)
Cytochrome P-450 Enzyme System/metabolism , Phenylalanine/metabolism , Threonine/metabolism , Base Sequence , Carbon Monoxide/metabolism , Crystallography , Cytochrome P-450 Enzyme System/chemistry , Cytochrome P-450 Enzyme System/genetics , Cytochrome P-450 Enzyme System/isolation & purification , DNA Primers , Escherichia coli/genetics , Hydrogen Bonding , Kinetics , Models, Molecular , Oxidation-Reduction , Spectrometry, Mass, Electrospray Ionization
2.
J Biol Chem ; 279(47): 48876-82, 2004 Nov 19.
Article in English | MEDLINE | ID: mdl-15364917

ABSTRACT

The nitrogenous pi -acceptor ligand 4-cyanopyridine (4CNPy) exhibits reversible ligation to ferrous heme in the flavocytochrome P450 BM3 (Kd=1.8 microm for wild type P450 BM3) via its pyridine ring nitrogen. The reduced P450-4CNPy adduct displays unusual spectral properties that provide a useful spectroscopic handle to probe particular aspects of this P450. 4CNPy is competitively displaced upon substrate binding, allowing a convenient route to the determination of substrate dissociation constants for ferrous P450 highlighting an increase in P450 substrate affinity on heme reduction. For wild type P450 BM3, Kd(red)(laurate)=82.4 microm (cf. Kd(ox)=364 microm). In addition, an unusual spectral feature in the red region of the absorption spectrum of the reduced P450-4CNPy adduct is observed that can be assigned as a metal-to-ligand charge transfer (MLCT). It was discovered that the energy of this MLCT varies linearly with respect to the P450 heme reduction potential. By studying the energy of this MLCT for a series of BM3 active site mutants with differing reduction potential (Em), the relationship EMLCT + (3.53 x = Em 17,005 cm)(-1) was derived. The use of this ligand thus provides a quick and accurate method for predicting the heme reduction potentials of a series of P450 BM3 mutations using visible spectroscopy, without the requirement for redox potentiometry.


Subject(s)
Bacterial Proteins/chemistry , Coloring Agents/pharmacology , Cytochrome P-450 Enzyme System/chemistry , Mixed Function Oxygenases/chemistry , Nitriles/pharmacology , Pyridines/pharmacology , Spectrophotometry/methods , Bacterial Proteins/genetics , Binding Sites , Binding, Competitive , Cytochrome P-450 Enzyme System/genetics , Dose-Response Relationship, Drug , Escherichia coli/metabolism , Fatty Acids/chemistry , Heme/chemistry , Iron/chemistry , Kinetics , Ligands , Mixed Function Oxygenases/genetics , Models, Chemical , Mutation , NADPH-Ferrihemoprotein Reductase , Nitriles/chemistry , Oxidation-Reduction , Point Mutation , Protein Binding , Pyridines/chemistry , Substrate Specificity , Thermodynamics , Ultraviolet Rays
SELECTION OF CITATIONS
SEARCH DETAIL
...